hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06359990, orgStudyIdInfo id: RushUMCEmezue, briefTitle: BrotherlyACT: A Culturally Congruent and Technology-Enhanced Youth Violence and Substance Use Intervention for Black Boys and Men, acronym: BrotherlyACT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2026-02-15, completionDateStruct date: 2026-02-15, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Rush University Medical Center, class: OTHER, descriptionModule briefSummary: This study will adapt and test a culturally tailored, multi-component, and trauma-focused digital intervention to reduce the risk and effects of youth violence and substance use and bridge service access gaps for young Black males (YBM) in pediatric emergency and community-based low-resource settings., conditionsModule conditions: Violence in Adolescence, conditions: Substance Use, conditions: Avoidance of Healthcare, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: BrotherlyACT, interventions name: BrotherlyACT Waitlist Control Group (WCG), outcomesModule primaryOutcomes measure: The Reactive-Proactive Aggression Questionnaire (RPQ), primaryOutcomes measure: Multidimensional Peer Victimization Scale (MPVS), primaryOutcomes measure: The Alcohol Use Disorders Identification Test (AUDIT), primaryOutcomes measure: Drug Use Disorders Identification Test (DUDIT), primaryOutcomes measure: Change in Attitude toward Substance Use, secondaryOutcomes measure: Emotional Avoidance Strategy Inventory for Adolescents (EASI-A), secondaryOutcomes measure: The Kessler Psychological Distress Scale (K-10), secondaryOutcomes measure: The University of Rhode Island Change Assessment Scale (URICA), secondaryOutcomes measure: Intensity-of-Care Measurements, secondaryOutcomes measure: Violent Intentions-Teen Conflict Survey, eligibilityModule sex: MALE, minimumAge: 15 Years, maximumAge: 24 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Rush University Medical Center, status: RECRUITING, city: Chicago, state: Illinois, zip: 60612, country: United States, contacts name: Chuka N Emezue, PhD, MPH, role: CONTACT, phone: 312-942-6151, email: chuka_emezue@rush.edu, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06359977, orgStudyIdInfo id: YB-202442, briefTitle: The Effect of Quantitative EEG Combined With Ultrasound and Sputum Volume on Predicting Weaning Failure, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-04-15, completionDateStruct date: 2025-05-15, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Qingdao University, class: OTHER, descriptionModule briefSummary: Neurocritical patients often face the need for removal of endotracheal tubes. However, despite following the extubation criteria for general critical ill patients, neurocritical patients still exhibit a higher rate of weaning failure, significantly higher than that of general critical ill patients. The extubation criteria for general critical patients emphasize the assessment of lung conditions. However, neurological critical patients often have less severe lung damage, but factors such as consciousness level and coughing ability may significantly influence extubation. Quantitative EEG serves as an objective tool to reflect consciousness level status, while bedside ultrasound can assess respiratory muscle function. Additionally, sputum volume may reflect the condition of lung condition. Therefore, we believe that combination of these three indicators can better predict the success of extubation for neurocritical patients., conditionsModule conditions: Weaning Failure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Quantitative EEG monitoring and beside ultrasound evaluation, outcomesModule primaryOutcomes measure: Quantitative EEG indicators, primaryOutcomes measure: Respiratory muscles thickness in centimeter, primaryOutcomes measure: Respiratory muscles thickening fraction (%), primaryOutcomes measure: Sputum volume in milliliter, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06359964, orgStudyIdInfo id: CRE2023.195, briefTitle: Infective Complications in TP Biopsy Without Antibiotic Prophylaxis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-03-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Chinese University of Hong Kong, class: OTHER, descriptionModule briefSummary: This study is a prospective cohort study to delineate the infective outcomes and incidence after transperineal prostate biopsy with no antibiotic prophylaxis, compared to the existing data on outcomes on patients receiving transperineal prostate biopsy with antibiotic prophylaxis., conditionsModule conditions: Prostate Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 1900, type: ESTIMATED, armsInterventionsModule interventions name: Transperineal Biopsy without antibiotics prophylaxis, interventions name: Transperineal Biopsy with antibiotics prophylaxis, outcomesModule primaryOutcomes measure: The difference in UTI hospitalization rate between the two groups after biopsy, primaryOutcomes measure: The difference in urosepsis rates between the two groups after biopsy, secondaryOutcomes measure: Post-biopsy UTI rates between the two groups, secondaryOutcomes measure: Assessment of bacteriology and antibiotic resistant profile between the two groups, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06359951, orgStudyIdInfo id: 24-0103, briefTitle: Implementation of Project YES in Ambulatory Adolescent & Young Adult Medicine, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-29, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2026-01-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Ann & Robert H Lurie Children's Hospital of Chicago, class: OTHER, collaborators name: American Psychological Association Division 53 Society for Clinical Child & Adolescent Psychology, descriptionModule briefSummary: This study tests a suite of single-session intervention (SSI) targeting risk factors for depression and eating disorders among adolescents and young adults. Youth ages 13-25 who screen positive for depression or anxiety as a part of routine care will be offered one of three digital SSIs. Participants will complete questionnaires before the intervention, immediately after the intervention, and 3-months after completing the intervention so that the study team can investigate if Project YES leads to reductions in depression, anxiety and eating disorder symptoms., conditionsModule conditions: Depression, conditions: Eating Disorders, conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Project YES, outcomesModule primaryOutcomes measure: Short Mood and Feelings Questionnaire (SMFQ; Messer et al., 1995), primaryOutcomes measure: Patient Health Questionnaire-9 (PHQ-9), primaryOutcomes measure: Generalized Anxiety Disorder -7 (GAD-7), secondaryOutcomes measure: Dietary Restriction Screener - 2 (DRS 2), secondaryOutcomes measure: Adult State Hope Scale, secondaryOutcomes measure: Self-Hate Scale, secondaryOutcomes measure: Beck Hopelessness -4, secondaryOutcomes measure: Program Feedback Scale, eligibilityModule sex: ALL, minimumAge: 13 Years, maximumAge: 25 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Ann & Robert H Lurie Children's Hospital of Chicago, city: Chicago, state: Illinois, zip: 60611, country: United States, contacts name: Anna M Ros, PhD, role: CONTACT, phone: 312-227-5433, email: annaros@luriechildrens.org, contacts name: Lisa Kuhns, PhD, role: CONTACT, phone: 312-227-6119, email: lkuhns@luriechildrens.org, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06359938, orgStudyIdInfo id: Cer22/01, briefTitle: Respiratory Sinus Arrhythmia Pacing Post-CABG Surgery in Patients With HFrEF, acronym: RSA-PACE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Ceryx Medical Ltd, class: INDUSTRY, collaborators name: Cardiff and Vale University Health Board, descriptionModule briefSummary: The goal of this clinical trial is to test a new type of pacemaker in heart failure patients following a heart bypass operation. The new pacemaker restores respiratory sinus arrhythmia which is a natural pattern where the heart rate increases when the participants breathe in and slows down when participants breathe out.The main questions the trial aims to answer are:* Is the new type of pacemaker safe?* Does the new type of pacemaker improve how patients' hearts work (also known as cardiac output)?Participants will have a range of tests before their operation and during their recovery in hospital while participants have the new type of pacemaker in place, and will be monitored very closely. Participants will also receive a phone call 1 month after their surgery. Researchers will compare the new type of heart pacing against standard treatment to see if it is as safe, and if it is any better for patients., conditionsModule conditions: Heart Failure With Reduced Ejection Fraction, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Atrial pacing with respiratory sinus arrhythmia (RSA) variability, interventions name: Monotonic right atrial overdrive pacing, outcomesModule primaryOutcomes measure: Number of arrhythmia episodes per patient during pacing, eligibilityModule sex: ALL, minimumAge: 22 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cardiff & Vale University Health Board, city: Cardiff, zip: CF14 4XW, country: United Kingdom, contacts name: Zaheer Yousef, role: CONTACT, email: CAV_research.development@wales.nhs.uk, contacts name: Avraj Virdi, role: CONTACT, geoPoint lat: 51.48, lon: -3.18, hasResults: False
protocolSection identificationModule nctId: NCT06359925, orgStudyIdInfo id: Suprazygomatic nerve block, briefTitle: Suprazygomatic Nerve Block in Tonsillectomy Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-10-22, primaryCompletionDateStruct date: 2025-09-20, completionDateStruct date: 2026-02-20, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: The use of suprazygomatic maxillary nerve block to reduce postoperative pain and hospital stay is greater than the use of NSAID and opioids., conditionsModule conditions: Tonsillectomy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Suprazygomatic maxillary nerve block using dexmedetomidne and Bupivacaine, interventions name: Suprazygomatic maxillary nerve block using Bupivacaine, outcomesModule primaryOutcomes measure: time and amount of first postoperative rescue analgesia after two different blocks using Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) score, secondaryOutcomes measure: time and amount of first postoperative rescue analgesia after two different blocks using Paediatric Anaesthesia Emergence Delirium (PAED) scale, secondaryOutcomes measure: Parents satisfaction score, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06359912, orgStudyIdInfo id: CNYX-EPCs-002-1, briefTitle: Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Allife Medical Science and Technology Co., Ltd., class: INDUSTRY, collaborators name: First Affiliated Hospital Xi'an Jiaotong University, descriptionModule briefSummary: The purpose of this study is to determine if allogeneic Endothelial Progenitor Cells (EPCs) intravenous infusion to a subject with leg ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain, increase blood flow, and/or cure the leg wound., conditionsModule conditions: Critical Limb Ischemia, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 27, type: ESTIMATED, armsInterventionsModule interventions name: EPCs, interventions name: Clinical standard treatment (CST), outcomesModule primaryOutcomes measure: adverse events, secondaryOutcomes measure: Painless walking and intermittent claudication distance, secondaryOutcomes measure: Blood flow of the affected limb, secondaryOutcomes measure: Rutherford grade, secondaryOutcomes measure: The area of skin ulcer, secondaryOutcomes measure: Vascular Quality of Life Questionnaire-6 score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hui Shi, status: RECRUITING, city: Beijing, state: Beijing, country: China, contacts name: Shaoying Lu, Dr, role: CONTACT, phone: +862985323473, phoneExt: +862985323473, email: xjyfyllh@163.com, contacts name: Fanggang Li, role: CONTACT, phone: 86-18911352611, email: lifanggang@allifetech.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06359886, orgStudyIdInfo id: FMASU MD 292/2022, briefTitle: B-lynch Transverse Compression Suture, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Alexandria University, class: OTHER, descriptionModule briefSummary: Is B-Lynch transverse compression suture safe and effective in controlling excessive blood loss during conservative management of women with placenta previa?, conditionsModule conditions: Blood Loss, Surgical, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: A Pilot Study, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: B-Lynch Transverse Compression Suture, outcomesModule primaryOutcomes measure: Intraoperative blood loss, primaryOutcomes measure: Postoperative blood loss, primaryOutcomes measure: Number of received blood components, primaryOutcomes measure: Peripartum haemoglobin level drop, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ain Shams University, status: RECRUITING, city: Cairo, zip: 21526, country: Egypt, contacts name: Ahmed S Zeerban, Msc, role: CONTACT, phone: +201003119968, email: Ahmedzeerban@gmail.com, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06359873, orgStudyIdInfo id: LAD-AF, briefTitle: Left Atrial Enlargement: A Crucial Indicator for Identifying Atrial Fibrillation in Patients With Hypertension, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-05-01, primaryCompletionDateStruct date: 2022-09-30, completionDateStruct date: 2023-05-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: The Second Affiliated Hospital of Chongqing Medical University, class: OTHER, descriptionModule briefSummary: Based on the data of inpatients with hypertension and a cross-sectional study with a large sample size, this study aims to find the early warning value of the left anteroposterior atrial diameter for the possible occurrence of atrial fibrillation in patients with hypertension, and compare the advantages and disadvantages of the above two methods for the early warning of the risk of atrial fibrillation in patients with hypertension, so as to achieve the purpose of early identification of high-risk groups that may develop atrial fibrillation., conditionsModule conditions: Atrial Fibrillation, conditions: Hypertension,Essential, conditions: Left Atrial Dilatation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 58427, type: ACTUAL, armsInterventionsModule interventions name: CHA2DS2-VASc score, C2HEST score, and left atrial diameter (LAD), outcomesModule primaryOutcomes measure: left atrial diameter (LAD), primaryOutcomes measure: CHA2DS2-VASc score, primaryOutcomes measure: C2HEST score, primaryOutcomes measure: Atrial fibrillation (AF), secondaryOutcomes measure: Area under the curve (AUC) of LAD and occurrence of AF, secondaryOutcomes measure: AUC of CHA2DS2-VASc score and occurrence of AF, secondaryOutcomes measure: AUC of C2HEST score and occurrence of AF, otherOutcomes measure: the LAD cutoff value, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: 2ndChongqingMU, city: Chongqing, state: Chongqing, zip: 400010, country: China, geoPoint lat: 29.56278, lon: 106.55278, hasResults: False
protocolSection identificationModule nctId: NCT06359847, orgStudyIdInfo id: ST-1898-202, briefTitle: Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-15, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Beijing Scitech-Mq Pharmaceuticals Limited, class: INDUSTRY, descriptionModule briefSummary: ST-1898, a multi-targeted tyrosine kinase inhibitor, has demonstrated strong inhibitory activity for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT, etc. The primary purpose of this study is to evaluate the efficacy of ST-1898 tablets in patients with locally advanced or metastatic RAIR-DTC after failure of at least first-line TKI systemic therapy. All subjects will receive ST-1898 180 mg orally once daily until disease progression or intolerable toxicity., conditionsModule conditions: Differentiated Thyroid Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: ST-1898 tablets, outcomesModule primaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: The number and frequency of treatment-related adverse events (AEs) and treatment related serious adverse events (SAEs), secondaryOutcomes measure: PFS, secondaryOutcomes measure: PFS6m, secondaryOutcomes measure: DCR, secondaryOutcomes measure: DOR, secondaryOutcomes measure: OS, secondaryOutcomes measure: Thyroglobulin (Tg), secondaryOutcomes measure: Thyroglobulin Antibody (TgAb), secondaryOutcomes measure: Pharmacokinetic (PK) Parameter: Tmax, secondaryOutcomes measure: Pharmacokinetic (PK) Parameter: T1/2, secondaryOutcomes measure: Pharmacokinetic (PK) Parameter: Cmax, secondaryOutcomes measure: Pharmacokinetic (PK) Parameter: AUC, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking Union Medical College Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100730, country: China, contacts name: Yansong Lin, MD, role: CONTACT, contacts name: Xin Zhang, MD, role: CONTACT, contacts name: Yansong Lin, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06359834, orgStudyIdInfo id: 4-2023-1693, briefTitle: Comparison of Remimazolam and Propofol Effect on Oxygen Reserve During Endoscopic Retrograde Cholangiopancreatography, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2025-04-10, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Yonsei University, class: OTHER, descriptionModule briefSummary: Propofol is one of the most commonly used sedative in endoscopic procedures, while its potency to induce respiratory depression may threaten patient safety. Remimazolam is known to less likely induce hemodynamic instability when compared to propofol, yet its favorable effects are not clearly evaluated in endoscopic procedures. Hence, this study aimed to compare hemodynamic effects of remimazolam and propofol, by evaluating oxygen reserve index (ORI) in patients scheduled for endoscopic retrograde cholangiopancreatography., conditionsModule conditions: Hepatobiiliary Diseases Requiring Endoscopic Retrograde Cholangiopancreatography, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 112, type: ESTIMATED, armsInterventionsModule interventions name: Remimazolam besylate, interventions name: Propofol, outcomesModule primaryOutcomes measure: Incidence of Oxygen Reserve Index (ORI) drop to 0.00 during sedation, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, status: RECRUITING, city: Seoul, zip: 120-752, country: Korea, Republic of, contacts name: Moon Jae Chung, MD, role: CONTACT, phone: +82-2-2228-1981, email: mjchung@yuhs.ac, geoPoint lat: 37.566, lon: 126.9784, hasResults: False